ENHANCEMENT OF SOLUBILITY OF POORLY SOLUBLE DRUG LANSOPRAZOLE
DOI:
https://doi.org/10.22159/ijap.2022.v14ti.14Keywords:
Lansoprazole, Solubility enhancement, PEG, Solid dispersionAbstract
Objective: To improve the solubility of lansoprazole with solid dispersion (SD) method by using hydrophilic polymer PEG 6000, PEG 15000 and amphiphilic polymer solupus.
Methods: Solid dispersions of lansoprazole were prepared with polymers PEG 6000, PEG 15000 and amphiphilic polymer soluplus, using three methods of preparation–1) solvent melting 2) solvent evaporation and 3) microwave heating method along with different drug: carrier ratios. Performance of the prepared formulations were evaluated for solubility, fourier transform infrared (FTIR) spectroscopy, and differential scanning calorimetry (DSC) parameters.
Results: All SDs showed enhancement in solubility of lansoprazole. Solubility and also carrier concentration showed a positive effect on solubility. The lansoprazole-soluplus solid dispersion 1:3 in concentration showed enhanced aqueous solubility when formulated with a solvent melting procedure.
Conclusion: The studies indicated that PEG 6000, PEG 15000 and Soluplus inhibite crystallization of lansoprazole, subsequently form amorphous state in solid dispersion, which is, confirmed via FTIR and DSC results of lansoprazole solid dispersion.
Downloads
References
Mutha S, Shelke V. Formulation and evaluation of lansoprazole sublingual tablet. JRP. 2020;24(2):264-76. doi: 10.35333/jrp.2020.143.
Garnett WR. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996 Dec;30(12):1425-36. doi: 10.1177/106002809603001212, PMID 8968456.
Maiden LP, Harris AW. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin. N Engl J Med. 2002 Nov 14;347(20):1623-4. doi: 10.1056/NEJM200211143472016, PMID 12432054.
Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001 Nov;96(11):3089-98. doi: 10.1111/j.1572-0241.2001.05263.x. PMID 11721754.
Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A. Current concepts in the management of helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther. 2002 Feb;16(2):167-80. doi: 10.1046/j.1365-2036.2002.01169.x. PMID 11860399.
Errata. J Clin Gastroenterol J Clin Gastroenterol. 1998;26(3):232-3. doi: 10.1097/00004836-199804000-00023.
Nikghalb LA, Singh G, Kahkeshan KF. Solid dispersion: methods and polymers to increase the solubility of poorly soluble drugs. J Appl Pharm Sci. 2012 Oct;2(10):170-5.
Bhasin N. Current trends in solid dispersion: a review. J Drug Delivery Ther. 2014;4(3):80-6. doi: 10.22270/jddt.v4i3.869.
Rangarajan N, Sangeetha R, Mohanasundaram S, Sampath, Porkodi K, Dass Prakash MV. Additive inhibitory effect of the peels of Citrus limon and Citrus sinensis against amylase and glucosidase activity. IJRPS 2020;11(4):6876-80. doi: 10.26452/ijrps.v11i4.3661.
Garg T. An approach for improvement of the water solubility of gliclazide in solid dispersion with PEG 4000. Int J Pharm Sci Res. 2011;2(6):1600-2.
Baka E, Comer JE, Takacs Novak K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as the model compound. J Pharm Biomed Anal. 2008 Jan 22;46(2):335-41. doi: 10.1016/j.jpba.2007.10.030. PMID 18055153.
Kavitha R, Sathali AH. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci. 2012;10(1):377-90.
Neha A, Singh I, Sharma M, Tarun G. An approach for improvement of the water solubility of nimesulide in solid dispersion with peg 4000. IOSR J Pharm. 2012;2(2):153-4.
Nasir AS, Jain AM, Bari MM, Chavan RB, Barhate SD. New dimensions to solid dispersion. Indo Am J Pharm Res. 2013;3(4):3246-55.
Lu Y, Guo T, Qi J, Zhang J, Wu W. Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modeling. AAPS PharmSciTech. 2012 Dec;13(4):1222-9. doi: 10.1208/s12249-012-9842-z. PMID 22968546, PMCID PMC3513431.
Patil I, Mane R, Randive D, Bhutkar M, Patil O. Formulation optimization and evaluation of Cefdinir nanosuspension using 23 Factorial design. JRP. 2018;22(1):257-68. doi: 10.12991/jrp.2018.101.
Published
How to Cite
Issue
Section
Copyright (c) 2022 SWATI MUTHA, VISHAL SHELKE, KANCHAN GUPTA, MRUNALINI KULKARNI, AMRITA THAKUR, NEETA RAI
This work is licensed under a Creative Commons Attribution 4.0 International License.
